Objective: Compare and study the use of metformin and DPP-4 inhibitors in conjunction with currently used combination treatments. Materials and Methods: In this 16-week study, sitagliptin and pioglitazone were compared as add-on treatments for type 2 diabetes mellitus patients whose condition was not sufficiently controlled by metformin alone. In addition to metformin, 52 patients were randomly assigned to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2). Change in HbA1c served as the main efficacy end objective. Changes in body weight, lipid profile, and fasting plasma glucose (FPG) were considered secondary end objectives. HbA1c significantly dropped in both groups. Results: In neither group did the mean FPG reductions differ significantly from one another. In group 1, the mean body weight and body mass index significantly decreased, while the same variables significantly increased in group 2. High density lipoprotein (HDL-C) and triglyceride levels significantly dropped in both therapy groups, according to the reports. Conclusion: The drug was well tolerated and did not cause any instances of hypoglycemia. It was determined that pioglitazone was not as effective or well tolerated as sitagliptin when added to metformin.

Objective: Compare and study the use of metformin and DPP-4 inhibitors in conjunction with currently used combination treatments. Materials and Methods: In this 16-week study, sitagliptin and pioglitazone were compared as add-on treatments for type 2 diabetes mellitus patients whose condition was not sufficiently controlled by metformin alone. In addition to metformin, 52 patients were randomly assigned to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2). Change in HbA1c served as the main efficacy end objective. Changes in body weight, lipid profile, and fasting plasma glucose (FPG) were considered secondary end objectives. HbA1c significantly dropped in both groups. Results: In neither group did the mean FPG reductions differ significantly from one another. In group 1, the mean body weight and body mass index significantly decreased, while the same variables significantly increased in group 2. High density lipoprotein (HDL-C) and triglyceride levels significantly dropped in both therapy groups, according to the reports. Conclusion: The drug was well tolerated and did not cause any instances of hypoglycemia. It was determined that pioglitazone was not as effective or well tolerated as sitagliptin when added to metformin.